Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
2 registry-linked trialsAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 93 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 6 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer
Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients
Who cites it
93 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials.Breast cancer research and treatment · 2026Pooled it
- A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence.International journal of molecular sciences · 2026Pooled it
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.Current oncology (Toronto, Ont.) · 2026Guideline
- [Systemic treatment of breast cancer: professional guideline].Magyar onkologia · 2025Guideline
- Long-term efficacy of CDK4/6 inhibitors in early HR+, HER2- high-risk breast cancer: An updated systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.ESMO open · 2024Guideline
- Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Trial
- Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.Breast cancer research and treatment · 2026Trial
- Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.Journal of the National Cancer Institute · 2025Trial
- Trial
- Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial.Breast cancer research and treatment · 2024Trial
- Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Trial
- Optimizing Extended Adjuvant Endocrine Therapy in Early HR+/HER2- Breast Cancer: The Emerging Role of Genomic Assays and ctDNA MRD.Advances in therapy · 2026Review
- Article
- Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Article
- Article
- A Telemedicine-Supported Home-Injection Model for Patients With Breast Cancer.JAMA network open · 2026Article
- De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.Breast (Edinburgh, Scotland) · 2026Observational
- Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer.Cancer medicine · 2026Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors.
Olivia PaganiInterdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Vaud, Switzerland.
Barbara A WalleyUniversity of Calgary and Canadian Cancer Trials Group, Calgary, AB, Canada.ORCID 0000-0002-9618-905X
Gini F FlemingThe University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL.ORCID 0000-0003-2845-4023
Marco ColleoniDivision of Medical Senology, IEO, European Institute of Oncology, IRCCS, and International Breast Cancer Study Group, Milan, Italy.ORCID 0000-0002-5743-3013
István LángClinexpert-research, Budapest, Hungary (prior affiliation).
Henry L GomezInstituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
Carlo TondiniOsp. Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo, Italy.
Harold J BursteinSusan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School and Alliance for Clinical Trials in Oncology, Boston, MA.ORCID 0000-0003-1963-8162
Matthew P GoetzMayo Clinic and Alliance for Clinical Trials in Oncology, Rochester, MN.ORCID 0000-0002-4383-270X
Eva M CiruelosMedical Oncology Department, University Hospital 12 de Octubre and SOLTI Breast Cancer Research Cooperative Group, Madrid, Spain.ORCID 0000-0002-2796-1042
Vered StearnsJohns Hopkins Sidney Kimmel Comprehensive Cancer Center and ECOG-ACRIN, Baltimore, MD.ORCID 0000-0003-4018-4708
Hervé R BonnefoiInstitut Bergonié Comprehensive Cancer Centre, Université de Bordeaux, INSERM U1312, and European Organisation for Research and Treatment of Cancer (EORTC), Bordeaux, France.ORCID 0000-0003-4293-9748
Silvana MartinoThe Angeles Clinic and Research Institute and SWOG, Santa Monica, CA.
Charles E GeyerUniversity of Pittsburgh Medical Center Hillman Cancer Center and NRG Oncology, Pittsburgh, PA.
Claudio ChiniDeaprment of Medical Oncology, Ospedale di Circolo e Fondazione, Lombardy, Italy.
Fabio PuglisiDepartment of Medicine (DAME), University of Udine, Italy and Department of Medical Oncology, IRCCS, Centro di Riferimento Oncologico CRO di Aviano, Aviano, Italy.ORCID 0000-0003-0573-4938
Simon SpazzapanDepartment of Medical Oncology, IRCCS, Centro di Riferimento Oncologico CRO di Aviano, Aviano, Italy.ORCID 0000-0003-3922-4960
Thomas RuhstallerUniversity of Basel, Swiss Group for Clinical Cancer Research (SAKK) and International Breast Cancer Study Group, Basel, Switzerland.
Eric P WinerSusan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School and Alliance for Clinical Trials in Oncology, Boston, MA.ORCID 0000-0002-8819-1723
Barbara RueppInternational Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
Sherene LoiInternational Breast Cancer Study Group and Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0001-6137-9171
Alan S CoatesInternational Breast Cancer Study Group and University of Sydney, Sydney, Australia.ORCID 0000-0002-0141-7356
Richard D GelberInternational Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, Boston, MA.ORCID 0000-0001-8270-8712
Aron GoldhirschEuropean Institute of Oncology, IRCCS, International Breast Cancer Study Group, Milan, Italy.
Meredith M ReganInternational Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-2428-6109
Prudence A FrancisPeter MacCallum Cancer Center, St Vincent's Hospital, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.ORCID 0000-0002-7207-9286
SOFT and TEXT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation)
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MNRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MMember Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MStatistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam, GREG YOTHERS · 2014 to 2026
$146.4MNRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2MNCIC Clinical Trials Group - Canadian Collaborating Clinical Trials NetworkU10CA180863 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI Janet Ellen Dancey · 2014 to 2026
$40.4MUT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1UG1CA233329 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KELLY K HUNT, CHELSEA Camille PINNIX · 2019 to 2026
$11.1MIBCSG STATISTICAL CENTER--A BREAST CANCER STUDY RESOURCEU24CA075362 · NCI · DANA-FARBER CANCER INSTITUTE · PI REGAN, MEREDITH M · 1997 to 2015
$7.5MUM LAPs -UG1 GrantUG1CA233160 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANNE F SCHOTT · 2019 to 2026
$5.4MCancer Research UK C1491/A15955Cancer Research UK CRUKE/03/022Cancer Research UK CRUKE/03/023NCI NIH HHS P30 CA006973NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180863NCI NIH HHS U10 CA180868NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA075362NCI NIH HHS UG1 CA189867NCI NIH HHS UG1 CA233160NCI NIH HHS UG1 CA233329
Abstract
PubMed holds no abstract for this paper.
Indexed as
Breast NeoplasmsAdjuvants, ImmunologicAdultAndrostadienesAntineoplastic Agents, HormonalChemotherapy, AdjuvantDisease-Free SurvivalFemaleFollow-Up StudiesHumansPremenopauseTamoxifenAdjuvants, ImmunologicAndrostadienesAntineoplastic Agents, HormonalexemestaneTamoxifen
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT00066703ClinicalTrials.gov
NCT07151911ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.